[email protected]
Phone: 406-994-4707; Fax: 406-994-4303
Mark T. Quinn, Ph.D., Professor, Department of Microbiology & Immunology and Director, WIMU Regional Program in Veterinary Medicine, Montana State University, Bozeman
Education:
Point Loma College, San Diego, CA; 1982; B.A. in Biology and Chemistry
University of California, San Diego, CA; 1987; PhD in Physiology and Pharmacology
The Scripps Research Institute, La Jolla, CA; 1988-1989; Postdoctoral Research Associate
Dr Quinn received Ph.D. training in Pharmacology and Physiology from the University of California at San Diego and worked on defining the role of oxidized low density lipoprotein in monocyte/macrophage chemotaxis during atherosclerosis. Since that time, his research has focused on studying inflammatory disease and innate immunity, and he has an established a research program in leukocyte biochemistry and immunopharmacology. As Postdoctoral Fellow at The Scripps Research Institute, Dr. Quinn performed studies investigating the composition and assembly of the human neutrophil NADPH oxidase and identified a novel regulatory GTPase involved in NADPH oxidase regulation. In addition, he performed extensive work characterizing intracellular signaling events associated with phagocyte activation during inflammation. In recent work, he has performed studies on innate immune cells, host defense mechanisms, and pharmacological effects of immunomodulatory compounds. Most recently, he is focusing his efforts on the identification and characterization of synthetic small-molecule compounds with immunomodulatory and anti-inflammatory activity. These studies involve small molecule screening, medicinal chemistry, structure-activity relationship (SAR) analysis, molecular modeling, and pharmacological analysis using in vitro and in vivo approaches.
Phone: 406-994-4707; Fax: 406-994-4303
Mark T. Quinn, Ph.D., Professor, Department of Microbiology & Immunology and Director, WIMU Regional Program in Veterinary Medicine, Montana State University, Bozeman
Education:
Point Loma College, San Diego, CA; 1982; B.A. in Biology and Chemistry
University of California, San Diego, CA; 1987; PhD in Physiology and Pharmacology
The Scripps Research Institute, La Jolla, CA; 1988-1989; Postdoctoral Research Associate
Dr Quinn received Ph.D. training in Pharmacology and Physiology from the University of California at San Diego and worked on defining the role of oxidized low density lipoprotein in monocyte/macrophage chemotaxis during atherosclerosis. Since that time, his research has focused on studying inflammatory disease and innate immunity, and he has an established a research program in leukocyte biochemistry and immunopharmacology. As Postdoctoral Fellow at The Scripps Research Institute, Dr. Quinn performed studies investigating the composition and assembly of the human neutrophil NADPH oxidase and identified a novel regulatory GTPase involved in NADPH oxidase regulation. In addition, he performed extensive work characterizing intracellular signaling events associated with phagocyte activation during inflammation. In recent work, he has performed studies on innate immune cells, host defense mechanisms, and pharmacological effects of immunomodulatory compounds. Most recently, he is focusing his efforts on the identification and characterization of synthetic small-molecule compounds with immunomodulatory and anti-inflammatory activity. These studies involve small molecule screening, medicinal chemistry, structure-activity relationship (SAR) analysis, molecular modeling, and pharmacological analysis using in vitro and in vivo approaches.
quinn_cv_2018.pdf | |
File Size: | 316 kb |
File Type: |
Phone: 406-994-4703. Fax: 406-994-4303.
[email protected]
Igor Schepetkin (Shchepetkin): PhD, Senior Research Scientist, Department of Microbiology & Immunology, Montana State University, Bozeman.
Education:
Tomsk Medical University, Russia. 1985; M.Sc. in Clinical Biophysics
Cancer Research Center of Russian Academy of Medical Sciences (RAMS), Tomsk, Russia; 1992; PhD in Oncology & Immunology.
Worked at Cancer Research Center of RAMS (Tomsk, Russia) for 17 years (1985-1999, 2002-2004) and investigated a role of antioxidant enzymes in tumor growth and the immunomodulatory effects of radiosensitizers and electron-acceptor compounds (Sanazole and other nitro-compounds). Dr. Schepetkin worked for 2 years 2000-2001) at Immunomodulation Research Center, University of Ulsan, South Korea and made research on immunomodulatory properties of Shilajit. In 2004 Igor moved to Montana, where he joined Mark Quinn's lab at MSU. His current research is focused on the discovery and development of agonists/antagonists of formyl peptide receptors (FPR1/FPR2/FPR3), inhibitors of c-Jun N-terminal Kinase (JNK), and human neutrophil elastase (HNE), anthrax lethal factor, superoxide dismutase (SOD) mimics and plant-derived antioxidants and immunomodulators. Authored more than 90 publications in peer-reviewed journals in fields of medicine chemistry, pharmacology, and immunology.
[email protected]
Igor Schepetkin (Shchepetkin): PhD, Senior Research Scientist, Department of Microbiology & Immunology, Montana State University, Bozeman.
Education:
Tomsk Medical University, Russia. 1985; M.Sc. in Clinical Biophysics
Cancer Research Center of Russian Academy of Medical Sciences (RAMS), Tomsk, Russia; 1992; PhD in Oncology & Immunology.
Worked at Cancer Research Center of RAMS (Tomsk, Russia) for 17 years (1985-1999, 2002-2004) and investigated a role of antioxidant enzymes in tumor growth and the immunomodulatory effects of radiosensitizers and electron-acceptor compounds (Sanazole and other nitro-compounds). Dr. Schepetkin worked for 2 years 2000-2001) at Immunomodulation Research Center, University of Ulsan, South Korea and made research on immunomodulatory properties of Shilajit. In 2004 Igor moved to Montana, where he joined Mark Quinn's lab at MSU. His current research is focused on the discovery and development of agonists/antagonists of formyl peptide receptors (FPR1/FPR2/FPR3), inhibitors of c-Jun N-terminal Kinase (JNK), and human neutrophil elastase (HNE), anthrax lethal factor, superoxide dismutase (SOD) mimics and plant-derived antioxidants and immunomodulators. Authored more than 90 publications in peer-reviewed journals in fields of medicine chemistry, pharmacology, and immunology.
"Phone: 406-994-4703, Fax: 406-994-4303
[email protected]
Liliya Kirpotina, MS., Postdoctoral Research Assocoate
Education: Graduated from the Tomsk Medical University, Russia, with the honor. 1988: MS in clinical biochemistry
She was working at the Department of Immunology and Microbiology for 4 years, then did projects at the Departments of Hematology and Pharmacology. Here she investigated the role of Cytochrome P450 in the liver ischemia and CCl4-induced hepatitis, screened the natural and newly synthesized compounds for SAR analysis, that lead her into the PhD program at the Department of Pharmacology, 1988-1990. She was interested in the liver energy balance, and how the inducers of the Cytochrome P450 altered it in order to find their effective application at different pathological conditions. Then she combined her work as a mother of 3 kids with the education at the pedagogical college (Montessori system and an innovative approach to music education for children, known as the "Orff Schulwerk") and work in the early development childcare center, oncology center and the medical insurance company. In 2004 Liliya moved to the USA, where she joined Mark Quinn's group for the screening of 10,000 library of synthetic compounds. This multiple high throughput screening resulted in the finding of the new hits for the modulation of innate immune system through FPRs, TLRs, TNF and MAPK pathways. Also, she screened the library of natural compounds, as well as extracts isolated from the the growing in Montana plants, (such as juniper, Artemisia, cactus, fire-weed, tansy), rhododendrons from Africa, and essential oils from the Kazakhstan's endemics.
[email protected]
Liliya Kirpotina, MS., Postdoctoral Research Assocoate
Education: Graduated from the Tomsk Medical University, Russia, with the honor. 1988: MS in clinical biochemistry
She was working at the Department of Immunology and Microbiology for 4 years, then did projects at the Departments of Hematology and Pharmacology. Here she investigated the role of Cytochrome P450 in the liver ischemia and CCl4-induced hepatitis, screened the natural and newly synthesized compounds for SAR analysis, that lead her into the PhD program at the Department of Pharmacology, 1988-1990. She was interested in the liver energy balance, and how the inducers of the Cytochrome P450 altered it in order to find their effective application at different pathological conditions. Then she combined her work as a mother of 3 kids with the education at the pedagogical college (Montessori system and an innovative approach to music education for children, known as the "Orff Schulwerk") and work in the early development childcare center, oncology center and the medical insurance company. In 2004 Liliya moved to the USA, where she joined Mark Quinn's group for the screening of 10,000 library of synthetic compounds. This multiple high throughput screening resulted in the finding of the new hits for the modulation of innate immune system through FPRs, TLRs, TNF and MAPK pathways. Also, she screened the library of natural compounds, as well as extracts isolated from the the growing in Montana plants, (such as juniper, Artemisia, cactus, fire-weed, tansy), rhododendrons from Africa, and essential oils from the Kazakhstan's endemics.